Medicine and Dentistry
Prostate Cancer
100%
Transitional Cell Carcinoma
90%
Kidney Metastasis
83%
Nephroureterectomy
71%
Recurrent Disease
68%
Targeted Therapy
63%
Clear Cell Renal Cell Carcinoma
58%
Neoplasm
54%
Prostate Specific Antigen
54%
Malignant Neoplasm
46%
Multivariate Analysis
41%
Biopsy Technique
38%
Neutrophil
37%
Lymphocyte
35%
C Reactive Protein
30%
Chemotherapy
28%
Needle Biopsy
28%
Overall Survival
26%
Disease
22%
Sunitinib
22%
Robot-Assisted Prostatectomy
22%
Nivolumab
22%
Survival Rate
22%
Progression Free Survival
22%
Prognostic Factor
21%
Cancer Specific Survival
21%
Molecularly Targeted Therapy
20%
Hazard Ratio
20%
Recurrence Free Survival
19%
Fibrinogen
18%
Disease Exacerbation
17%
Prostatectomy
17%
High Risk Population
17%
Metastatic Carcinoma
16%
Adverse Event
14%
Liver Metastasis
13%
Survival Prediction
13%
Androgen Deprivation Therapy
13%
Cisplatin
13%
Cancer Staging
13%
Surgeon
12%
Nephrectomy
12%
Risk Stratification
12%
Docetaxel
12%
Notch
11%
IgG4-Related Disease
11%
Transrectal Ultrasonography
11%
Prostate Hypertrophy
11%
Urinary Tract Obstruction
11%
Pembrolizumab
11%
Pharmacology, Toxicology and Pharmaceutical Science
Kidney Metastasis
67%
Transitional Cell Carcinoma
67%
Recurrent Disease
50%
Castration Resistant Prostate Cancer
36%
Pharmacodynamics
33%
Prostatitis
33%
C Reactive Protein
33%
Chemotherapy
31%
Prostate Specific Antigen
30%
Overall Survival
30%
Malignant Neoplasm
30%
Prostate Cancer
28%
Neoplasm
27%
Renal Cell Carcinoma
24%
Sunitinib
22%
Clinical Pharmacokinetics
22%
Cabazitaxel
22%
Surgical Infection
22%
Progression Free Survival
22%
Minimum Inhibitory Concentration
21%
Survival Rate
19%
Drug Concentration
18%
Disease
18%
Disease Exacerbation
17%
Androgen
17%
Interleukin 6
16%
Adverse Event
14%
Liver Metastasis
13%
Survival Prediction
13%
Docetaxel
12%
Pembrolizumab
11%
Piperacillin Plus Tazobactam
11%
Pazufloxacin
11%
Urinary Tract Obstruction
11%
Biochemical Recurrence
11%
Epididymitis
11%
Abiraterone Acetate
11%
Axitinib
11%
Cachexia
11%
Alternative Complement Pathway C3 C5 Convertase
11%
Nuclear Factor
11%
Bicalutamide
11%
Fibrinogen
11%
Cisplatin
11%
Pharmacokinetics
11%
Flomoxef
11%
Non Muscle Invasive Bladder Cancer
11%
Erdafitinib
11%
Cancer Specific Survival
10%
Gleason Score
9%
Keyphrases
Targeted Therapy
34%
Upper Tract Urothelial Carcinoma
33%
Metastatic Renal Cell Carcinoma (mRCC)
29%
Nephroureterectomy
26%
Multi-institution
22%
Prostate Cancer
22%
Pharmacodynamics Target Attainment
22%
Cancer-specific Survival
21%
Neutrophil-to-lymphocyte Ratio
17%
Recurrent Disease
16%
Risk Factors
16%
Multivariate Analysis
15%
Multi-institutional
12%
Multi-institutional Study
12%
Second-line Treatment
12%
Prostate Tissue
11%
Transrectal Ultrasound
11%
Memorial Sloan-Kettering Cancer Center
11%
Cancer Prevention
11%
Cancer Tissue
11%
Tumor Extent
11%
Open Gastrectomy
11%
Inflammatory Markers
11%
Progression-free Survival
11%
C-X-C Chemokine Receptor Type 4 (CXCR4)
11%
Patient Outcomes
11%
External Validation
11%
Prognostic Value
11%
Plasma Fibrinogen
11%
Prostate-specific Antigen Response
11%
Dorsal Venous Complex
11%
Endopelvic Fascia
11%
Disease Impact
11%
Therapeutic Agents
11%
Therapy Initiation
11%
Castration-resistant Prostate Cancer Cells
11%
Urinary Tract Obstruction
11%
Bladder Outcome
11%
Preoperative Nomogram
11%
Relative Dose Intensity
11%
Regulatory T Cells
11%
Dose Intensity
11%
Human Prostate Tissue
11%
Prognostic Stratification
11%
Poor Prognosis
11%
Metastatic Behavior
11%
Dehydroxymethylepoxyquinomicin (DHMEQ)
11%
Surgical Site Infection
11%
Nuclear factor-B
11%
Cytoreductive Nephrectomy
11%